An unusual cutaneous manifestation of ulcerative colitis: thrombotic skin gangrene

Suveer Singh, Kai Noshirwani

Summary
Ulcerative colitis has a number of associated skin lesions. We report the case of a patient with active ulcerative disease presenting with rapidly progressive necrotic skin lesions, identified as thrombotic and requiring skin grafting. Thrombotic cutaneous gangrene is a rare but potentially serious manifestation of uncontrolled ulcerative colitis.

Keywords: ulcerative colitis, microvascular thrombosis, skin gangrene

A 57-year-old Caucasian man with a 10-year history of controlled ulcerative colitis presented with right iliac fossa pain and bloody diarrhoea. Colonoscopy revealed inflammation extending throughout the large bowel and biopsies were consistent with ulcerative colitis. He was commenced on intravenous steroids.

Over the previous 10 years, his ulcerative colitis had been well controlled on aminosalicylic acids. However, during this period he had been admitted several times with venous occlusions, three deep vein thromboses in the legs, a right axillary vein occlusion and more recently a suspected right gluteal vein thrombosis. His long-term anticoagulation had been stopped seven years earlier for unspecified reasons.

Three days following admission, he developed a painful superficial haemorrhagic area below the left nipple. Within 24 hours it had progressed to occupy the left anterior aspect of the abdominal wall (figure). The next day two similar lesions appeared in the right loin and nipple areas, respectively. A swelling of the right leg was confirmed as a deep vein thrombosis on venography. He was anticoagulated with intravenous heparin as a 5000-unit loading dose followed by an infusion of 1400 units/h, adjusted to maintain an activated partial thromboplastin time at 2–2.5 times the base value.

Investigations revealed a normocytic anaemia (haemoglobin 11.3 g/dl), white cell count $13 \times 10^9$ g/l and normal platelet count, erythrocyte sedimentation rate, coagulation screen, cryoglobulins, antiphospholipid antibody titres, proteins C and S and antithrombin III levels, prior to anticoagulation. Skin biopsy of the haemorrhagic lesion demonstrated a full thickness infarction, capillaritis, and microthrombi in the dermal vessels with extensive erythrocyte extravasation; the findings were nonspecific but not consistent with pyoderma gangrenosum.

A putative diagnosis of skin infarction secondary to thrombosis of small cutaneous vessels was made. It was hoped that intravenous heparin for the deep vein thrombosis would also help his skin lesions. While anticoagulated, the cutaneous lesions did not progress, and in fact the smaller lesions appeared to regress two days into treatment. However, the initial skin lesion broke down, requiring a full thickness skin graft. It is likely that this area had already infarcted prior to the commencement of heparin.

Despite the presence of active colitis, blood loss during anticoagulation was not a major problem, as evidenced by stable haemoglobin levels. However, his ulcerative colitis did not settle with medical treatment, and he underwent a total colectomy six weeks after admission.

Discussion
Cutaneous manifestations of ulcerative colitis include erythema nodosum, erythema nodosum, and the potentially serious pyoderma gangrenosum, which is the most specific of its

Figure Superficial haemorrhagic infarct over left anterior chest wall
Summary points

- There is an increased thrombophilic tendency in ulcerative colitis.
- Thrombotic skin gangrene is a rare cutaneous manifestation of ulcerative colitis, histologically distinct from pyoderma gangrenosum.
- Progression to full thickness skin infarction is a potentially serious complication.
- A thrombophilia screen and skin biopsy should be performed prior to early anticoagulation.

Skin associations. Thrombotic cutaneous gangrene is a rare complication of ulcerative colitis, quite distinct histologically from pyoderma gangrenosum, and has been reported infrequently to date. Similar lesions have been described in the past and more recently by Stapleton et al, who treated their patient's skin condition successfully with intravenous heparin prior to the development of full thickness infarction.

Microvascular focal thrombosis is thought to be the basis of this cutaneous gangrene. There is an increased incidence of thromboembolic phenomena associated with ulcerative colitis. Five per cent of ulcerative colitis sufferers develop deep vein thrombosis, whilst there are reports of increased cerebral venous thromboses. This increased clotting tendency may result from raised levels of clotting factors V, VIII and fibrinogen and a fall in antithrombin III levels due to protein-losing enteropathy, while circulating cryoglobulins are another potential cause of cutaneous gangrene. Furthermore, recent reports have shown increased platelet counts in ulcerative colitis-associated thromboembolic disease. The management of such gangrenous skin lesions is not clearly established, although reports of resolution following prednisolone and intravenous heparin have set a basis for treatment. Bleeding complications due to anticoagulation in the presence of active colitis appear not to have arisen from previous reports. However, should significant bleeding be a problem, there is some evidence of a reduced haemorrhagic tendency and similar efficacy of low molecular weight heparin as an alternative to unfractionated heparin, albeit in other settings.

We reiterate the importance of early suspicion of cutaneous gangrene if unusual skin lesions, that do not conform to pyoderma gangrenosum, appear in inflammatory bowel disease. A full thrombophilic blood screen should be done, and early anticoagulation with heparin, aiming to prevent progressive cutaneous infarction. The role of intravenous steroids in the treatment of ulcerative colitis-associated cutaneous gangrene remains unclear, other than for treating the exacerbation of colitis.

An unusual cutaneous manifestation of ulcerative colitis: thrombotic skin gangrene.
S. Singh and K. Noshirwani

doi: 10.1136/pgmj.72.852.623

Updated information and services can be found at:
http://pmj.bmj.com/content/72/852/623

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/